Chicago, IL Tomorrow s Cancer Treatments Today

Cancer and Leukemia Group B Summer Group Meeting June 24-26, 2010 / Chicago, IL Tomorrow’s Cancer Treatments Today Schedule / Meeting Information / ...
Author: May Burns
2 downloads 3 Views 1MB Size
Cancer and Leukemia Group B Summer Group Meeting June 24-26, 2010 / Chicago, IL

Tomorrow’s Cancer Treatments Today

Schedule / Meeting Information / Agendas

Inside

2

3 n Meeting Schedule At-a-Glance 4 n Meeting Highlights 5 n Agendas 5 Plenary Session 5 Disease Committees 5 Breast 6 GI 7 GU 7 Leukemia/Leukemia Correlative Sciences 9 Lymphoma 10 Respiratory 12 Modality Committees 12 Cancer Control and Health Outcomes 12 Cancer in the Elderly 13 Pharmacology and Experimental Therapeutics 13 Transplant 15 Scientific Resource Committees 15 Clinical Research Associates 15 Pathology 16 Radiation Oncology 16 Surgery 16 Workshops / Forums 16 CARE Forum 17 Correlative Science Symposium 17 CRA Continuing Education 17 CRA Workshop for Cancer Control Studies 17 Oncology Nursing/Pharmacy Joint Educational Session 18 n Service Recognition 20 n Onsite Details Inside Back Cover / Hotel Floor Plans Back Cover / Acknowledgements

Cancer and Leukemia Group B Summer Group Meeting 2010

Welcome to Chicago! 2010 Cancer and Leukemia Group B Summer Group Meeting In the 54-year history of the CALGB, there has never been a time with greater potential for success than the present. The time is ripe for advances, and CALGB is positioned to achieve greater success than ever before. Dedication, hard work, a sense of purpose and professional collegiality – these qualities are ingrained in the CALGB culture – and that is how we have achieved our current position. Moving forward, we must maintain a connected community of clinical and translational researchers with the knowledge and imagination necessary to develop innovative studies. We will continue to design our studies for the real world of cancer care, and conduct them with the high level of professionalism necessary to perform optimally in an environment of limited resources. The key to our success will be to continue to have an attitude of openness to collaboration of all kinds, and a proactive approach that gets us over barriers to progress. Have a great meeting! Sincerely,

Monica M. Bertagnolli, M.D. Group Chair

4

Cancer and Leukemia Group B Summer Group Meeting 2010

M e e t i n g S c hedule A t- a- G la n c e All sessions are being held at The Fair mont Chicago.

THURSDAY/June 24 8 1 2 3 3 4 4 6

am - 7 pm pm - 2:45 pm pm - 4 pm pm - 5 pm pm - 5 pm pm - 7 pm pm - 8 pm pm - 9 pm

Registration/Information Desk International ballroom Foyer / 2nd level CRA Committee / General Session gold room / 2nd level Oncology Nurses Scientists Closed Session diplomat ROOM / 3rd level CRA Committee / CRA Orientation state room / 2nd level CRA Committee / Advanced Session GOLD room / 2nd level Oncology Nursing Committee Closed Session diplomat ROOM / 3rd level GCO/SC/CO Directors Meeting Closed Session crystal room / 3rd level CARE Patient Advocacy Subcommittee Closed Session regent room / 3rd level

FRIDAY/June 25 7 am - 7 pm 7:30 am - 12 pm 8 am - 12 pm 9 am - 11 am 9 am - 1 pm 10 am - 12 pm 10 am - 12:30 pm 11 am - 12 pm 11 am - 4 pm 12 pm - 1:30 pm 12:30 pm - 3:30 pm 12:30 pm - 4 pm 1 pm - 4 pm 1 pm - 4 pm 1 pm - 4 pm 1:30 pm - 3 pm 2 pm - 4 pm 3 pm - 4 pm 3 pm - 5 pm 4 pm - 6 pm 4 pm - 7 pm 4:30 pm - 7:30 pm 7 pm - 10 pm

Registration/Information Desk International ballroom Foyer / 2nd level Extended Executive Committee Closed Session moulin rouge / lobby level CRA Continuing Education Session Gold room / 2nd level Lung Tissue Bank Governance Meeting Closed Session royal room / lower level SoCRA Certification Exam state room / 2nd level Oncology Nurses/Pharmacy Joint Educational Session crystal room / 3rd level Imaging Committee regent room / 3rd level Constitution Committee Closed Session diplomat room / 3rd level Data and Safety Monitoring Board Closed Session regal Room / lower level Audit Committee Closed Session royal room / lower level PET Committee moulin rouge room / lobby level Jimmie Holland Lecture/CCHO Committee crystal room / 3rd level Radiation Oncology Committee regent room / 3rd level GI Committee international ballroom / 2nd level Leukemia/Leukemia Correlative Sciences Committees gold Room / 2nd level IPEC Committee Closed Session chancellor room / 3rd level Pharmacy Committee Closed Session diplomat room / 3rd level chancellor room / 3rd level Membership Committee Closed Session CALGB Specimen Tracking System (STS) Kiosk international BALLROOM foyer / 2nd level CARE Forum / Making Clinical Trials Count for Everyone state room / 2nd level Board of Directors Closed Session Moulin rouge room / lobby level gold room / 2nd level Transplant Committee Reception and Dinner** international ballroom / 2nd level

**Join colleagues and make new friends at the Cancer and Leukemia Group B Reception and Dinner, and experience Chicago’s contemporary fine dining.

SATURDAY/June 26 7 am - 6 pm 7 am - 9 am 7:30 am - 9 am 7:30 am - 9 am 8 am - 10 am 9 am - 11 am 9 am - 11 am 9 am - 12 pm 9 am - 12 pm 10 am - 12 pm 12 pm - 1:30 pm 12 pm - 1:30 pm 12 pm - 1:30 pm 1:30 pm - 4 pm 4 pm - 5 pm 4 pm - 6 pm 4 pm - 6 pm 4 pm - 6 pm 4 pm - 7 pm 4 pm - 7 pm

Registration/Information Desk International ballroom Foyer / 2nd level Pathology Committee regent room / 3rd level Surgery Committee state room / 2nd level CALGB Foundation Board of Trustees Breaskfast Closed Session moulin rouge / lobby level CALGB Specimen Tracking System (STS) Kiosk international BALLROOM foyer / 2nd level Surgical Quality Assurance Review Committee regal room / lower level Correlative Science Symposium gold room / 2nd level Breast Committee International ballroom / 2nd level Lymphoma Committee crystal room / 3rd LEVEL CRA Workshop for Cancer Control Studies Chancellor Room / 3rd level Biospecimen and Correlative Sciences Advisory Closed Session gold room / 2nd level PI Forum Closed Session moulin rouge room / lobby level Young Investigators Luncheon By Invitation Only regent room / 3rd level PLENARY SESSION Registration/Information Desk Closed Imperial ballroom / lower level Conflict of Interest Committee Closed Session regal room / lower level Cancer in the Elderly state room / 2nd level CCHO Steering Committee Closed Session embassy room / 2nd level CCOP Committee chancellor room / 3rd level GU Committee gold room / 2nd level Respiratory Committee international ballroom / 2nd level

Cancer and Leukemia Group B Summer Group Meeting 2010

3

Meeting Highlights

THURSDAY/June 24 CRA Committee Meeting 1 pm - 5 pm, Various Rooms (see schedule on page 3) This year’s meeting will be presented in three sessions: a general session and two special breakout sessions. In the general session, CALGB Central Office and Statistical Center staff will discuss policies changes that impact CRAs in their day-to-day jobs and new information about studies, forms and data clarification issues. Then, attendees will move into one of two breakouts sessions: one for newer CRAs with less than 18 months experience (CRA Orientation) and the other for those who are more experienced (Advanced Session) to discuss issues relevant to their current roles. In the Advanced Session, William Sikov, M.D., of Miriam Hospital in Providence, RI, will lead discussion on two CALGB neoadjuvant breast cancer trials (CALGB 40601 and 40603), and focus on trial design, logistics of patient enrollment, and successful accrual strategies.

FRIDAY/June 25 Oncology Nurses/Pharmacy Joint Educational Sesson 10 am - 12 pm, Crystal Room, 3rd Level Genetics has an increasing role in cancer prevention, treatment, and research, and understanding its implications is increasingly important for all healthcare professions, including physicians, nurses, pharmacists, and CRAs. This session, “DNA and Cancer: Using genetics to help predict cancer risks and treatment response,” will feature highly-knowledgeable speakers who will provide current information on indications for cancer genetic counseling and the pharmacogenomics of cancer treatments. Featured speakers include Bonnie R. Braddock, M.P.H., C.G.C., Senior Certified Genetic Counselor in the Section of Medical Genetics at Upstate Medical University in Syracuse, NY, and R. Donald Harvey, Pharm.D., F.C.C.P., B.C.P.S., B.C.O.P., Assistant Professor, Hematology/Medical Oncology, and Director of the Phase I Unit at the Winship Cancer Institute of Emory University in Atlanta, GA. 10th Annual Jimmie Holland Lecture 12:30 pm - 1:30 pm, Crystal Room, 3rd Level Geriatrician and medical oncologist Arti Hurria, M.D., Director of the Cancer and Aging Research Program at City of Hope in Duarte, CA, will present this year’s 10th anniversary lecture on “Research in Geriatric Oncology: Meeting the Needs of an Aging Population.” CALGB Specimen Tracking System (STS) Kiosk 3 pm - 5 pm (Friday) and 8 am - 10 am (Saturday) International Ballroom Foyer, 2nd Level CALGB staff will be on hand to address any and all questions related to the newly released CALGB Specimen Tracking System (STS). For those who have not used STS yet, this is a great opportunity to learn more about how the system works in a small, personalized setting. More experienced users can take advantage of this forum to share comments about the system or to ask specific study- or specimen-related questions. 4

Cancer and Leukemia Group B Summer Group Meeting 2010

CARE Forum / Making Clinical Trials Count for Everyone: Teaming Up with CALGB Patient Advocates for Better Results 4 pm - 6 pm, State Room, 2nd Level Results and insights from a recent survey on the role of patient advocates in the CALGB presented at this year’s American Society of Clinical Oncology (ASCO) meeting will be discussed during this two-hour interactive session. Featured panelists include Ann Partridge, M.D., M.P.H., Assistant Professor in Medicine at Harvard Medical School; Kay Kays, a CALGB Patient Advocate; Richard Larson, M.D., Professor of Medicine and Director of the Hematologic Malignancies Program at the University of Chicago Medical Center; and Margaret White, R.N., O.C.N., C.C.R.P., Clinical Trials Director at New Hampshire Oncology-Hematology P.A.

SATURDAY/June 26 Correlative Science Symposium 9 am - 11 am, Gold Room, 2nd Level The CALGB Biospecimen and Correlative Sciences Advisory Committee sponsors this two-hour correlative science forum that highlights outstanding CALGB science and the promise of the biomarker field in advancing cancer treatment. This year’s symposium will focus on integral and integrated biomarkers with a special emphasis on the development and implementation of biomarkers guiding therapy – all presented by outstanding CALGB correlative science investigators: Pasi Janne, M.D., Ph.D., Dana-Farber Cancer Institute; Mary Ellen Moynahan, M.D., Memorial Sloan-Kettering Cancer Center; Klaus Metzeler, M.D., The Ohio State University; and Margaret Gulley, M.D., University of North Carolina at Chapel Hill. CRA Workshop for Cancer Control Studies 10 am - 12 pm, Chancellor Room, 3rd Level CRAs, data managers and nurses will learn about open CCHO Committee studies, specifically the design methods and recruitment strategies from study chairs. The workshop will be presented in an interactive format where the audience can ask specific questions about protocols and hear from the experts. This set-up is also ideal for study chairs, who are interested in hearing from staff “in the trenches” about obstacles to protocol enrollment and possible solutions.

Continuing Medical Education Credits Nursing / R.N., O.C.N., A.R.N.P. An application for approval of about nine contact hours of CE credit has been submitted to the Illinois Nurses Association. C.C.R.P. The Society of Clinical Research Associates (SoCRA) accepts documentation of candidate participation in the continuing education program for re-certification, if the program is applicable to clinical research regulations, operations or management, or to the candidate’s clinical research therapeutic area. This program offers up to 25 hours of CE credit.

plenary session Saturday/June 26, 1:30 pm – 4 pm, Imperial Ballroom, Lower Level Group Chair Remarks and Presentation Monica M. Bertagnolli, M.D. Group Chair Richard L. Schilksy CALGB Achievement Award John C. Byrd, M.D. The Ohio State University Medical Center Special Group Statistician Presentation Monica M. Bertagnolli, M.D. Group Chair Stephen L. George, Ph.D. Group Statistician

Breast Committee

Saturday/June 26, 9 am – 12 pm, International Ballroom, 2nd Level Co-Chairs Clifford Hudis, M.D. Eric Winer, M.D. Vice Chairs Matthew Ellis, M.B., B.Chir., Ph.D. Lyndsay Harris, M.D. Charles Perou, Ph.D. PI3K Pathway Targeting: Clinical Research Opportunities Sarat Chandarlapaty, M.D., Ph.D. Assistant Attending Memorial Sloan-Kettering Cancer Center Protocol Review Active 40101 Cyclophosphamide and doxorubicin(CA X 4 cycles) versus paclitaxel (4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: A phase III randomized study Lawrence Shulman, M.D. 40601 Randomized phase III trial of paclitaxel combined with trastuzumab, lapatinib, or both as neoadjuvant treatment of HER2-positive primary breast cancer Lisa Carey, M.D. 40603 Randomized phase II 2x2 factorial trial of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor- poor/HER2-negative resectable breast cancer William Sikov, M.D. 40503 Endocrine therapy with or without anti-VEGF therapy: A randomized phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC 704865: IND 7921) for women with hormone receptor-positive advanced breast cancer Maura Dickler, M.D. 40502 A randomized phase III trial of weekly paclitaxel com- pared to weekly nanoparticle albumin bound NAB-paclitaxel or ixabepilone combined with bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer Hope Rugo, M.D. 40302 Endocrine therapy with or without inhibition of EGF and HER2 growth factor receptors: A randomized, double- blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib (GW572016) for postmenopausal women with hormone receptor positive advanced breast cancer Harold Burstein, M.D., Ph.D. CTSU E5103 A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevaci- zumab or placebo in patients with lymph node positive and high-risk lymph node negative breast cancer Chau Dang, M.D. Subcommittee Reports Surgery David Ollila, M.D. Correlative Science Lyndsay Harris, M.D. Cancer and Leukemia Group B Summer Group Meeting 2010

5

Session Agendas

diSEase COMMITTEES

Session Agendas

Breast Committee continued In Development T-DM1 adjuvant Eribulin vs standard chemotherapy

Ian Krop, M.D.

Minetta Liu, M.D. Tamoxifen for CYP2d6 poor metabolizers George Raptis, M.D., and Myra Barginear, M.D. Treatment of brain metastases Nancy Lin, M.D.

GI Committee Friday/June 25, 1 pm – 4 pm, International Ballroom, 2nd Level Chair Alan Venook, M.D. Vice Chairs A. William Blackstock, M.D. Najjia Mahmoud, M.D. Perry Shen, M.D. Whither Gemcitabine? Hedy Kindler, M.D. Andrew Ko, M.D. Protocol Review 80702 A phase III trial of 6 v. 12 treatments of adjuvant FOLFOX with or without celecoxib therapy for patients with stage III colon cancer Jeffrey Meyerhardt, M.D., M.P.H. Active 80802 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) Ghassan Abou-Alfa, M.D. 80302 A phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer David Ilson, M.D., Ph.D. 80405 A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum Alan Venook, M.D. CTSU E5202 A randomized phase III study comparing 5-FU, leucovorin and oxaliplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine prospectively the prognostic value of molecular markers David Ryan, M.D. CTSU R-04 A clinical trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum David Ryan, M.D. CTSU Z6051 A phase III prospective randomized trial comparing laparoscopy assisted resection versus open resection for rectal cancer Martin Weiser, M.D. 6

Cancer and Leukemia Group B Summer Group Meeting 2010

CTSU E1208 A phase III randomized trial of chemoembolization with or without sorafenib in unresectable hepatocellular carcinoma (HCC) in patients with and without vascular invasion Bert O’Neil, M.D. In Development After resection of gastric or gastroesophageal adenocarcinoma Charles Fuchs, M.D., M.P.H. 81001 Neoadjuvant FOLFOX with selective use of combined modality chemoradiation for intermediate risk (T3N0, T1-3N1) rectal cancer Deborah Schrag, M.D. 81002/N0949 Randomized phase III trial of mFOLFOX7 + bevacizumab v. 5-FU or capecitabine + bevacizumab as first-line treatment in elderly patients (> 75 years old) with metastatic colorectal cancer Nadine Jackson, M.D. 80803 Phase II trial of PET Scan-directed combined modality therapy in esophageal cancer Karyn Goodman, M.D. Discussion Where Do We Go From Here? Hedy Kindler, M.D. Andrew Ko, M.D. 81003 Randomized phase II study of gemcitabine + Hh path- way inhibitor, or gemcitabine + erlotinib, followed by radiation with concurrent capecitabine, for patients with locally advanced pancreas cancer Andrew Ko, M.D. 80902 Phase III randomized study of imatinib mesylate therapy with or without early surgical resection for resectable metastatic GIST Chandrajit Raut, M.D. 80904 Sorafenib vs. imatinib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors: A random- ized phase II trial Hedy Kindler, M.D. 80701 Randomized phase II study of bevacizumab alone, in combination with everolimus, or in combination with temozolomide in patients with locally advanced or metastatic pancreatic neuroendocrine tumors Matthew Kulke, M.D., M.M. Sc. 80903 Prospective, randomized study of standard chemotherapy with/or without hepatic cytoreduction for patients with liver dominant metastatic CRC prior to receiving secondline chemotherapy Stephen Solomon, M.D., and Charles Cha, M.D. GI Surgery Subcommittee Report Perry Shen, M.D. GI Correlative Science Report Najjia Mahmoud, M.D.

Saturday/June 26, 4 pm – 7 pm, Gold Room, 2nd Level Chair Eric Small, M.D. Vice Chairs Phillip Febbo, M.D. James Mohler, M.D. Protocol Review Correlative Science Phillip Febbo, M.D. 150201 Laboratory studies in hormone refractory prostate cancer: A companion study to CALGB 9480 and 9583 150603 Laboratory studies in metastatic renal cell carcinoma: A companion study to CALGB 90206 Localized Prostate Cancer James Mohler, M.D. 140602 A phase III study of active surveillance therapy against radical treatment in patients diagnosed with favourable prostate cancer [START] 90203 A randomized phase III study of neo-adjuvant doc- etaxel and androgen deprivation prior to radical prostatec- tomy versus immediate radical prostatectomy in patients with high-risk, clinicallly localized protostate cancer 70807 A randomized multicenter phase III study of diet change for prostate cancer patients treated with active surveillance Bladder Cancer Jonathan Rosenberg, M.D. 90601 Randomized phase III study of gemcitabine and cispla- tin or gemcitabine, cisplatin, and bevacizumab in patients with advanced transitional cell carcinoma of the urinary tract 90801 Phase II study of twice-weekly gemcitabine and concurrent radiation in older patients with muscle-invasive bladder cancer who are not candidates for and/or refuse cystectomy Renal Cell Carcinoma Daniel George, M.D. 90802 Randomized phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal cell carcinoma progressing after treatment with tyrosine kinase inhibitors CTSU E2804 The BeST Trial: A randomized phase II study of VEGF, RAF kinase, mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib, temsirolimus in advanced renal cell carcinoma CTSU E2805 ASSURE: Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma Advanced Prostate Cancer Michael Morris, M.D. 90202 A randomized double-blind, placebo-controlled phase III study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone CTSU S0421 Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer 90902 Phase II trial of 153Sm-EDTMP, docetaxel, and bevacizumab in patients with metastatic castration resistant taxane-naive prostate cancer Advanced Prostate Cancer: A New Paradigm Moderator Michael Morris, M.D. Lessons Learned from 90401 W. Kevin Kelly, D.O. Endpoints in Prostate Cancer Howard Scher, M.D. Bone Targeted Therapy Matthew Smith, M.D. AR Rediscovered - The New Biology Edward Gelmann, M.D.

AR as Target Cabazitaxel - Implications Immunotherapy - The Post Provenge World

Charles Ryan, M.D. Oliver Sartor, M.D. Eric Small, M.D.

Leukemia/Leukemia Correlative Sciences Committees Friday/June 25, 1 pm – 4 pm, Gold Room, 2nd Level Leukemia Chair Richard Larson, M.D. Vice Chair Richard Stone, M.D. Correl Sci Chair Michael Caligiuri, M.D. Vice Chair John Byrd, M.D. New Developments in Blast Crisis CML Danilo Perrotti, M.D., Ph.D. Protocol Review 10503 Phase II study of maintenance therapy with decitabine (NSC# 127716, IND# 50733) following standard induction and cytogenetic risk-adapted intensification in previously untreated patients with AML < 60 years [EHA Abstract] William Blum, M.D. 9665 8461 20202 IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal AML Guido Marcucci, M.D. 10603 A phase III randomized, double-blind study of induc- tion (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC412) (IND# 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML) Richard Stone, M.D. 9665 8461 20202 FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA- expression signatures in patients 60+ years old with primary cytogenetically normal AML Susan Whitman, Ph.D. 11001 A phase II study incorporating sorafenib into the therapy of patients > 60 years of age with FLT-3 mutated acute myeloid leukemia Geoffrey Uy, M.D. 8528 8923 9720 10201 Treatment of older patients with de novo AML with one or more post-remission chemothera py courses – Analysis of four CALGB studies [ASCO abstract] Maria Baer, M.D. 9665 8461 20202 Higher MN1 expression is an unfavorable independent prognosticator in older [> 60 years] patients with cytogenetically normal AML [AACR Abstract] Sebastian Schwind, Ph.D. 11002 A randomized phase II study of decitabine-based induc- tion strategies for patients > 60 years old with acute myeloid leukemia Gail Roboz, M.D. 10404 A genetic risk-stratified, randomized phase II study of four fludarabine/antibody combinations for patients with symptomatic, previously untreated chronic lymphocytic leukemia John Byrd, M.D. Cancer and Leukemia Group B Summer Group Meeting 2010

7

Session Agendas

GU Committee

CARE FORUM

Making Clinical Trials Count for Everyone: Teaming Up with CALGB Patient Advocates for Better Results Friday, June 25 / 4 pm - 6 pm State Room / 2nd Level Join the CALGB Committee on Advocacy, Research Communication, Ethics and Disparities (CARE) for its annual forum – Making Clinical Trials Count for Everyone! Results and insights from a recent survey on the role of patient advocates in the CALGB presented at this year’s American Society of Clinical Oncology (ASCO) meeting will be discussed during this two-hour interactive session. Featured panelists include Ann Partridge, M.D., M.P.H., Assistant Professor in Medicine at Harvard Medical School; Kay Kays, a CALGB Patient Advocate; Richard Larson, M.D., Professor of Medicine and Director of the Hematologic Malignancies Program at the University of Chicago Medical Center; and Margaret White, R.N., O.C.N., C.C.R.P., Clinical Trials Director at New Hampshire OncologyHematology P.A.

10601 Randomized phase II trial of VRDox (bortezomib [Velcade®], lenalidomide [Revlimid®], and pegylated liposomal doxorubicin [Doxil®]) versus VRDex (bortezomib, lenalidomide, and dexamethasone) as initial therapy for adult patients with symptomatic multiple myeloma Asher Chanan-Khan, M.D. 10403 Intergroup phase II clinical trial for adolescents and young adults with untreated acute lymphoblastic leukemia (ALL) Wendy Stock, M.D. CTSU Intergroup Leukemia Studies Richard Larson, M.D.

Lymphoma Committee Saturday/June 26, 9 am – 12 pm, Crystal Room, 3rd Level Chair Bruce Cheson, M.D. Vice Chairs Andrew Zelenetz, M.D., Ph.D. John Leonard, M.D. Nancy Bartlett, M.D. New Drugs in Lymphoma, Inside and Out Bruce Cheson, M.D. John Leonard, M.D. Protocol Review Active Large Cell: Frontline 50303 Phase III randomized study of R-CHOP v. dose- adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphomas Wyndham Wilson, M.D., Ph.D. Follicular: Relapsed 50401 A randomized phase II trial of rituximab vs. lenalidomide (RevlimidTM, CC-5013) (IND #73034) vs. rituximab + lenalidomide in recurrent follicular non-Hodgkin lymphoma (NHL) that is not rituximab-refractory John Leonard, M.D. Mantle Cell: Frontline 50403 A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma Lawrence Kaplan, M.D.

Cancer and Leukemia Group B Summer Group Meeting 2010

9

Session Agendas

Leukemia/Leukemia Correlative Sciences Committees continued

Mantle Cell: Relapsed 50501 A phase II trial of bortezomib (NSC# 681239) + lenalidomide (Revlimid™, CC-5013) (NSC# 703813) for relapsed/refractory mantle cell lymphoma Vicki Morrison, M.D. Hodgkin: Frontline CTSU S0816 A phase II trial of response adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging Nancy Bartlett, M.D. 50801 Phase II trial of response-adapted therapy based on positron emission tomography (PET) for bulky stage I and stage II classical Hodgkin lymphoma (HL) Ann LaCasce M.D. 50604 Phase II trial of response-adapted chemotherapy based on positron emission tomography for non-bulky stage I and II Hodgkin lymphoma David Straus, M.D. In Development Follicular: Frontline 50803 Phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL) Rebecca Elstrom, M.D. 50901 A phase II trial of ofatumumab in previously untreated follicular non-Hodgkin’s lymphoma (NHL) Cara Rosenbaum, M.D. 50904 A randomized phase II trial of ofatumumab-benda- mustine vs. ofatumumab, bortezomib, and bendamustine in patients with untreated follicular lymphoma Kristie. Blum, M.D. Mantle Cell: Relapsed 50903 A phase II study of bortezomib plus ofatumumab for relapsed/refractory mantle cell lymphoma Sonali Smilth, M.D. T-Cell: Relapsed 51101 Phase II study of romidepsin and bortezomib in patient with relapsed or refractory aggressive T-cell lymphomas Francine Foss, M.D. Hodgkin: Relapsed 50906 A phase I/randomized phase II study comparing brentuximab vedotin (SGN-35) to brentuximab vedotin plus lenalidomide for patients with relapsed refractory classical Hodgkin lymphoma Todd Fehniger, M.D. Closed Hodgkin: Frontline 50203 Phase II trial of doxorubicin, vinblastine and gemcita bine (AVG) chemotherapy for non-bulky stage I and II Hodgkin lymphoma David Straus, M.D. Primary CNS 50202 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma James Rubenstein, M.D., Ph.D. Follicular: Frontline 50402 A phase II trial of extended induction galiximab (anti CD-80 monoclonal antibody) (BB-IND #12373) plus ritux- imab in previously untreated follicular non-hodgkin lymphoma Myron Czuczman, M.D.

Session Agendas

Lymphoma Committee continued



50701 A phase II trial of extended induction epratuzumab (anti- CD22 monoclonal antibody)(CALGB IND# 101241) plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL) Barbara Grant, M.D. Hodgkin: Relapsed 50602 A phase II study of galiximab (anti-CD80) for patients with relapsed/refractory Hodgkin lymphoma Sonali Smith, M.D.

Respiratory Committee Saturday/June 26, 4 pm – 7 pm, International Ballroom, 2nd Level Chair Everett Vokes, M.D. Vice Chairs Jeffrey Crawford, M.D. Robert Kratzke, M.D. Protocol Overview, Accrual and Manuscripts Everett Vokes, M.D., and Xiaofei Wang, Ph.D. Best of ASCO: In Lung Cancer Martin Edelman, M.D. Translational Research: New Insights into Mechanisms of Actions of TKI’s and Relevance to Current CALGB Trials Pasi Janne, M.D., Ph.D. First Line Stage IV Non-Small Cell Lung Cancer 30607 Randomized, phase III, double-blind placebo controlled trial of sunitinib (NSC# 736511, IND# 74019) as maintenance therapy in non-progressing patients following an initial four cycles of platinum-based combination chemo therapy in advanced, stage IIIB/IV non-small cell lung cancer Mark Socinski, M.D., and Maria Baggstrom, M.D. 30801 A randomized phase III study evaluating selective COX-2 inhibition in COX-2 overexpressing advanced non-small cell lung cancer Martin Edelman, M.D., Michael Maitland, M.D., Ph.D., and Robert Kratzke, M.D. CTSU S0819 A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC) Michael Perry, M.D. 30902 A randomized phase II trial of erlotinib alone or in combination with bevacizumab in patients with non-small cell lung cancer and activating epidermal growth factor receptor mutations Thomas Stinchcombe, M.D., and Pasi Janne, M.D., Ph.D. Proposal: Chemotherapy in Stage IV PS2 and Elderly NSCLC Rogerio Lilenbaum, M.D., Ajeet Gajra, M.D., and Jeffrey Crawford, M.D. Proposal: Exercise and Outcomes Around Survival Across All Stages of Lung Cancer Lee Jones, M.D. Second Line Non-Small Cell Lung Cancer 30704 A randomized phase II study to assess the efficacy of pemetrexed or sunitinib (NSC #736511, IND #74019) or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer Rebecca Suk-Heist, M.D., and Mark Socinski, M.D. 10

Cancer and Leukemia Group B Summer Group Meeting 2010

Early Stage Non-Small Cell Lung Cancer and Surgical Studies Todd Demmy, M.D. 140503 A phase III randomized trial of lobectomy versus limited resection for small ( 75 years old) with metastatic colorectal cancer Nadine Jackson, M.D.



Evaluation of memantine as a neuroprotector in elderly patients receiving prophylactic cranial radiotherapy for small cell lung carcinoma: Maintenance of cognitive function in elders with small cell lung cancer treated with cranial radiation John Grecula, M.D.

Pharmacology and Experimental Therapeutics Committee Friday/June 25, 12:30 pm – 3:30 pm, Moulin Rouge Room, Lobby Level Chair Mark Ratain, M.D. Vice Chairs Merrill Egorin, M.D. Howard McLeod, Pharm.D. Antonius Miller, M.D. Recent Advances in the Pharmacogenomics of Endocrine Agents for Breast Cancer James Ingle, M.D. Professor of Oncology Mayo Clinic Protocol Review Pharmacogenomic Studies: Overview of Completed, Active and Planned Studies Howard McLeod, M.D. Potential Barriers to Accrual to CALGB Pharmacogenomic Studies Lynn Dressler, Ph.D. Active 40101 Cycophophamide and doxorubicin (CA X 4 cycles) versus paclitaxel (4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: A phase III randomized study Deanna Kroetz, Ph.D. Federico Innocenti, M.D., Ph.D. 30607 Randomized, phase III, double-blind placebo controlled trial of sunitinib (NSC# 736511, IND# 74019) as maintenance therapy in non-progressing patients following an initial four cycles of platinum-based combination chemotherapy in advanced, stage IIIB/IV non-small cell lung cancer Michael Maitland, M.D., Ph.D.

30704 A randomized phase II study to assess the efficacy of pemetrexed or sunitinib (NSC #736511, IND #74019) or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer Michael Maitland, M.D., Ph.D. 19808 A randomized phase II study of induction chemp therapy with or without MDR-modulation with PSC-833 (NSC #648265, IND #41121) followed by cytogenetic risk- adapted intensification therapy followed by immunotherapy with rIL-2 (NSC #373364, IND #1969) vs. observation in previously untreated patients with AML < 60 years Merril Egorin, M.D. 150303 Gene ratios for prognosis in lung cancer using tissues from CALGB 9761 Merril Egorin, M.D. In Development Organ dysfunction studies Ghassan Abou-Alfa, M.D. Studies in the elderly Merril Egorin, M.D. Study of adherence, comprehension, and labeling in regard to oral anticancer therapy in breast cancer Lynn Dressler, Ph.D. Disease progression modeling of CALGB data Robert Bies, M.D. Simulation of phase II trials using resampling of CALGB phase III data Mani Sharma, M.D.



Transplant Committee Friday/June 25, 4:30 pm – 7:30 pm, Gold Room, 2nd Level Chair Charles Linker, M.D. Vice Chair Thomas Shea, M.D. Management of Chronic Graft Versus Host Disease (GVHD) Stephanie J. Lee, M.D., M.P.H. Attending Physician Fred Hutchinson Cancer Research Center ASCO Presentation: Results from CALGB 100104 Philip McCarthy, M.D. Protocol Review Active 100103 A phase II study of allogeneic transplant for older patients with AML in first morphologic complete remission using a non-myeloablative preparative regimen Steven Devine, M.D. 50403 A randomized phase II trial of maintenance vs con- solidation bortezomib therapy following agressive chemo immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma Lawrence Kaplan, M.D.

Cancer and Leukemia Group B Summer Group Meeting 2010

13

Session Agendas

90801 Phase II styudy of twice-weekly gemcitabine and con- current radiation in older patients with muscle-invasive bladder cancer who are not candidates for and/or refuse cystectomy Matthew Milowsky, M.D. 70803 Comorbidities and functional status in older breast cancer survivors Harvey Jay Cohen, M.D., and Alice Kornblith, Ph.D. Trials in elders with non-small cell lung cancer Jeffrey Crawford, M.D., and Rogerio Lilenbaum, M.D. 70805 A geriatric-specific phone-based psychotherapy for elderly cancer patients with depressive symptoms Alice Kornblith, Ph.D. , and Christian Nelson, Ph.D. 70802 Population-based assessment of cancer trial generalizability in the elderly Elizabeth Lamont, M.D., M.S. Treatment decision-making among older compared to younger adults with acute myeloid leukemia Richard Stone, M.D., and Heidi Klepin, M.D. Manuscript Status Update Future Research Directions New Ideas/New Business

Oncology Nurses/Pharmacy Joint Educational Session

Friday, June 25 10 am - 12 pm Crystal Room 3rd Level



















Cancer Genetic Counseling Bonnie Braddock, M.P.H., C.G.C. Senior Certified Genetic Counselor Section of Medical Genetics Upstate Medical University

Pharmacogenomics and Cancer Treatments

R. Donald Harvey, Pharm.D., F.C.C.P., B.C.P.S., B.C.O.P. Assistant Professor, Hematology/Medical Oncology Director, Phase I Unit Winship Cancer Institute Emory University

Committee continued

100701 Phase II study of reduced-intensity allogeneic stem cell transplant for high-risk chronic lymphocytic leukemia (CLL) Edwin Alyea, M.D. 100601 Reduced-intensity allogeneic hematopoietic cell transplantation as second transplantaton for patients with disease relapse or myelodysplasia after prior autologous transplantation Asad Bashey, M.D. BMT CTN 0701 Phase II trial of non-myeloablative allogeneic hematopoietic cell transplantation for patients with relapsed follicular non-Hodgkin’s lymphoma beyond first complete response Thomas Shea, M.D. BMT CTN 0702 A trial of single autologous transplant with or without RVD consolidation versus tandem transplant and maintenance therapy for patients with multiple myeloma Philip McCarthy, M.D. In Development 100801 Phase II study of the addition azacytidine to reduced- intensity conditioning allogeneic transplantation for myelo- dysplasia (MDS) and older patients with AML Ravi Vij, M.D. 100901 A phase II study of the allogenic stem cell transplantation using reduced intensity conditioning regimen for relapsed or high-risk peripheral T-cell lymphoma Leslie Andritsos, M.D. 10701 Dasatinib as primary therapy for Ph+ ALL Meir Wetzler, M.D. Closed 100104 A phase III randomized, double-blind study of maintenance therapy with CC-5013 (NSC# 703813, IND# 70116) or placebo following autologous stem cell transplantation for multiple myeloma Philip McCarthy, Jr., M.D. 10001 A phase II trial of sequential chemotherapy, imatinib mesylate (Gleevec, STI571) (NSC# 716051, IND# 61135), and transplantation for adults with newly diagnosed Ph+ acute lymphoblastic leukemia by the CALGB and SWOG Meir Wetzler, M.D. 10503 Phase II study of maintenance therapy with decitabine (NSC# 127716, IND# 50733) following standard induction and cytogenetic risk-adapted intensification in previously untreated patients with AML < 60 years William Blum, M.D. New Proposals Intensive mobilization strategy for autologous transplant for diffuse large cell lymphoma in second remission Babis Andreadis, M.D. Autologous transplant for mantle cell lymphoma – Successor to 50403 Thomas Shea, M.D.

SCIENTIFIC RESOURCE COMMITTEES

Session Agendas

transplant

Clinical Research Associates Committee Thursday/June 24, 1 pm – 5 pm, Various Rooms Kandie Dempsey, M.S., R.N., O.C.N., C.C.R.P. Vice Chair Barbara Barrett, M.S., C.C.R.P. General Session: 1 pm – 2:45 pm, Gold Room, 2nd Level Group Chair Address Monica M. Bertagnolli, M.D. CALGB Central Office Update Trini Ajazi, M.M. CALGB Statistical Center Update Susan Barry Clinical Trials Support Unit – OPEN Registration Training Diana Meyer OPEN Administrator Westat CALGB Specimen Tracking System (STS) Paula Friedman, Ph.D. CRA Orientation: 3 pm – 5 pm, State Room, 2nd Level CALGB Web Site Overview Susan Barry CALGB Online Training System Overview Kelly Colligan Data Management Overview Adverse Event Reporting Disease Response Susan Barry Advanced Session: 3 pm – 5 pm, Gold Room, 2nd Level ALTTO - Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial Lynne Flickinger, M.S. NCCTG Research Protocol Specialist Mayo Clinic Linda Veit, C.C.R.P. Stacy Drew, M.S., C.C.R.P.

Pathology Committee Saturday/June 26, 7 am – 9 am, Regent Room, 3rd Level Chair Eric Hsi, M.D. Vice Chairs Wendy Frankel, M.D. Scott Jewell, Ph.D. Multiplex Quantitative Tissue-based Biomarker Analysis Fiona Ginty, Ph.D. Senior Scientist Computational Biology and Biostatistics Lab GE Global Research

Cancer and Leukemia Group B Summer Group Meeting 2010

15

Wo r k s h o p s / F o r u m s

Radiation Oncology Committee Friday/June 25, 1 pm – 4 pm, Regent Room, 3rd Level Chair Jeffrey Bogart, M.D. Vice Chairs A. William Blackstock, M.D. Mark Hurwitz, M.D. Protocol Review Active 30605 A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small cell lung cancer Michael Samuels, M.D. 30609 A randomized phase III comparison of standard radiotherapy (63 Gy) versus high-dose conformal radiotherapy (74 Gy) with concurrent and consolidation carboplatin/pacli- taxel in patients with stage IIIA/IIIB non-small cell lung cancer A. William Blackstock, M.D., and Jeffrey Bogart, M.D. 30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide Jeffrey Bogart, M.D. 80302 Phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer Harvey Mamon, M.D., Ph.D. CTSU R-04 A clinical trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum Harvey Mamon, M.D., Ph.D., and A. William Blackstock, M.D. 50604 Phase II trial of response-adapted chemotherapy based on positron emission tomography for non-bulky stage I and II Hodgkin lymphoma John Grecula, M.D. 50801 Phase II trial of response-adapted therapy based on positron emission tomography (PET) for bulky stage I and stage II classical Hodgkin lymphoma (HL) Christopher Kelsey, M.D. 360901 Evaluation of memantine as a neuroprotector in patients receiving prophylactic cranial radiotherapy for small cell lung carcinoma John Grecula, M.D. 81001 Neoadjuvant FOLFOX without planned pelvic radiation therapy for good risk locally advanced rectal adeno- carcinoma Deborah Schrag, M.D. 80803 Phase II trial of PET scan-directed combined modality therapy in esophageal cancer Karyn Goodman, M.D. 90801 Phase II study of twice-weekly gemcitabine and concurrent radiation in older patients with muscle-invasive bladder cancer who are not candidates for and/or refuse cystectomy H. James Wallace, III, M.D. In Development Phase II study of gemcitabine + GDC-0449, a Hh pathway inhibitor, or gemcitabine + erlotinib, followed by RT with capecitabine, for locally advanced pancreatic cancer Stanley Liauw, M.D. 16 Cancer and Leukemia Group B Summer Group Meeting 2010

SBRT boost for intermediate-risk prostate cancer Sean Collins, M.D. Hypofx RT + chemo in medically inoperable NSCLC Joseph Salama, M.D. IGRT Hypofx RT + chemo for Stage III NSCLC James Urbanic, M.D.

Surgery Committee Saturday/June 26, 7:30 am – 9 am, State Room, 2nd Level Chair Leslie Kohman, M.D. Vice Chair Judy Smith, M.D. Opening Remarks Leslie Kohman, M.D. Introduction of Surgical Residents Leslie Kohman, M.D. Study Reports by Surgical Cadre Leaders Breast Surgery: David Ollila, M.D. GI Surgery: Perry Shen, M.D. GU Surgery: James Mohler, M.D. Thoracic Surgery: Todd Demmy, M.D. Surgery Quality Assurance: Judy Smith, M.D. Surgery Committee Initiatives Closing Remarks Leslie Kohman, M.D.

WORKSHOPS / FORUMS CARE Forum

Friday/June 25, 4 pm – 6 pm, State Room, 2nd Level CARE Chair Deborah Collyar Making Clinical Trials Count for Everyone: Teaming Up with CALGB Patient Advocates for Better Results CARE Update Deborah Collyar Survey Results from “The Role of Patient Advocates in CALGB” Ann Partridge, M.D., M.P.H. Patient Advocate Perspective Kay Kays Principal Investigator Perspective Richard Larson, M.D. Draft Action Plan to Improve Effectiveness Deborah Collyar Panel Discussion Moderator: Deborah Collyar Panelists: Kay Kays, CALGB Patient Advocate; Richard Larson, M.D., CALGB Leukemia Committee Chair; Olwen Hahn Lyon, M.D., CALGB Executive Officer; Paula Friedman, Ph.D., CALGB Director of Biospecimen and Correlative Science Operations; Margaret White, R.N., O.C.N, C.C.R.P., CALGB CRA Committee Member

Saturday/June 26, 9 am – 11 am, Gold Room, 2nd Level Biospecimen and Correlative Sciences Advisory Committee Chair Phillip Febbo, M.D. Introduction Phillip Febbo, M.D. EGFR Mutations and Response to Therapy in NCSLC Patients Pasi Janne, M.D., Ph.D. PIK3CA Mutations are Associated with Improved Outcome in Breast Cancer Mary Ellen Moynahan, M.D. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets within De Novo Cytogenetically Normal Acute Myeloid Leukemia Klaus Metzeler, M.D. Principles and Practices for Validating Clinical Molecular Pathology Tests Margaret Gulley, M.D.

CRA Continuing Education Friday/June 25, 8 am – 12 pm, Gold Room, 2nd Level CRA Committee Chair Kandie Dempsey, M.S., R.N., O.C.N., C.C.R.P. Vice Chair Barbara Barrett, M.S., C.C.R.P. Leukemia Review: Types, Diagnostics and Treatments Eyal Attar, M.D. Behind the Scenes at the Leukemia Tissue Bank  Donna Bucci Leukemia Research Historical Perspective: What Have We Learned?  John Byrd, M.D.

CRA Workshop Studies

for

Cancer Control

Saturday/June 26, 10 am – 12 pm, Chancellor Room, 3rd Level CCHO Committee Chair Electra Paskett, Ph.D. Vice Chair Ann Partridge, M.D., M.P.H. Protocols Active 70305 A randomized study to prevent lymphedema in women treated for breast cancer Electra Paskett, Ph.D. 70501 Collection of patient-reported symptoms and perfor- mance status via the internet [companion to 30607, 30704, 40502, 40503, 40601, 40603, 70604, 80405, 90401] Lauren Rogak, M.A. 70604 A randomized, phase III study of standard dosing versus longer dosing interval of zoledronic acid in metastatic cancer Andrew Himelstein, M.D. In Development 70806 Vitamin D and breast cancer markers Marie Wood, M.D. 70807 A randomized multicenter phase III study of diet change for prostate cancer patients treated with active surveillance James Marshall, Ph.D.

Oncology Nursing/Pharmacy Joint Educational Session Friday/June 25, 10 am – 12 pm, Crystal Room, 3rd Level Oncology Nursing Committee Chair Ellen M. Lavoie Smith, Ph.D., A.R.N.P., A.O.C.N. Pharmacy Committe Chair Christine Berard-Collins, M.B.A., R.Ph. Cancer Genetic Counseling Bonnie Braddock, M.P.H., C.G.C. Senior Certified Genetic Counselor Section of Medical Genetics Upstate Medical University Pharmacogenomics and Cancer Treatments R. Donald Harvey, Pharm.D., F.C.C.P., B.C.P.S., B.C.O.P. Assistant Professor, Hematology/Medical Oncology Director, Phase I Unit Winship Cancer Institute Emory University

Cancer and Leukemia Group B Summer Group Meeting 2010

17

Wo r k s h o p s / F o r u m s

Correlative Science Symposium

Ser vice Recognition 20 years Joanne Chilton

Data Management

02/19/1990

State University of New York Upstate Medical University

15 years Jane E. Russell

Data Management

05/01/1995

Dana-Farber Cancer Institute

Belenda B. Slate

Data Management

03/21/1995

Southeast Cancer Control Consortium, Inc.

10 years Anne M. Burgess

Oncology Nursing/Data Management

03/01/2000

Brigham and Women’s Hospital

Deborah A. Clark

Oncology Nursing

03/17/2000

University of Vermont

Angela L. Earles

Data Management

05/03/2000

Illinois Oncology Research Association

Beverly A. Fein

Oncology Nursing/Data Management

04/04/2000

University of California at San Francisco

Sharon McFadden

Data Management

02/18/2000

Wake Forest University School of Medicine

Nanette J. Nier

Oncology Nursing/Data Management

05/09/2000

North Shore University Hospital

5 years Lori L. Albrecht

Oncology Nursing

06/29/2005

LIncoln Medical Education Foundation Cancer Center

Lorena Bacon

Data Management

03/10/2005

Kaiser Permanente

Dawn R. Bolliger

Data Management

04/21/2005

Illinois Oncology Research Association

Alison J. Caccavale

Oncology Nursing

05/27/2005

Queens Hospital Center

Christine M. Cain

Oncology Nursing/Data Management

03/08/2005

Premier Oncology Hematology Associates

Jasmine H. Champagne

Oncology Nursing

03/30/2005

Kaiser Permanente

Kathleen A. Colson

Oncology Nursing

04/06/2005

Dana-Farber Cancer Institute

Pamela L. Crecelius

Oncology Nursing/Data Management

06/30/2005

St. Anthony’s Medical Center

Lisa C. Dixon

Data Management

07/14/1999

Wake Forest University School of Medicine

Carolyn P. Elliott

Oncology Nursing

03/30/2005

Kaiser Permanente

Jen S. Elmer

Data Management

06/21/2005

LIncoln Medical Education Foundation Cancer Center

Ellen S. Gilbert

Oncology Nursing/Data Management

03/03/2005

Sturdy Memorial Hospital, Inc.

Erica L. Green

Data Management

06/07/2005

Cedars-Sinai Medical Center

Debra Greene

Oncology Nursing/Data Management

02/17/2005

South Carolina Oncology Associates, PA

Margaret A. Haldoupis

Oncology Nursing

04/11/2005

Dana-Farber Cancer Institute

Kathy Hanke

Oncology Nursing/Data Management

06/16/2005

St. Joseph’s Medical Center

Sandy A. Huartson

Oncology Nursing/Data Management

04/11/2005

Grand Rapids Clinical Oncology Program

Maureen M. Jean

Oncology Nursing/Data Management

05/17/2005

Miriam Hospital

18

Cancer and Leukemia Group B Summer Group Meeting 2010

Tami A. Jenkins

Oncology Nursing

06/19/2005

Howard Regional Health System

Suzanne Jonas

Oncology Nursing

04/11/2005

Grand Rapids Clinical Oncology Program

Elizabeth A. Kasparian

Oncology Nursing

04/11/2005

Dana-Farber Cancer Institute

Colleen L. Lawrence

Oncology Nursing/Data Management

04/27/2005

Dana-Farber Cancer Institute

Angela Leach

Data Management

04/21/2005

Memorial Health University Medical Center

James W. Lee

Data Management

02/01/2005

Weill Medical College of Cornell University

Jennifer M. Long

Oncology Nursing/Data Management

02/24/2005

Norwalk Hospital

Erika S. Mack

Data Management

03/16/2005

Memorial Sloan-Kettering Cancer Center

Mary L. McKenney

Oncology Nursing

04/06/2005

Dana-Farber Cancer Institute

Marlene A. Miller

Oncology Nursing/Data Management

01/20/2005

Florida Hospital Cancer Institute

Linda K. Morse

Oncology Nursing/Data Management

02/17/2005

Dana-Farber Cancer Institute

Mary F. Quinn

Oncology Nursing

06/14/2005

University of Maryland Greenebaum Cancer Center

Kathleen A. Roche

Oncology Nursing

04/11/2005

Dana-Farber Cancer Institute

Monica A. Schaefer

Data Management

01/03/2005

Northern Indiana Cancer Research Consortium

Nancy A. Soehnlein

Oncology Nursing

02/01/2005

Roswell Park Cancer Institute

Teal Stocker

Oncology Nursing/Data Management

04/08/2005

Florida Hospital Cancer Institute

Antoinette Michelle Thomas

Oncology Nursing/Data Management

06/28/2005

Carson Tahoe Hospital

Brendal T. Thomas

Oncology Nursing/Data Management

01/20/2005

Kaiser Permanente

Carrie A. Turner

Data Management

05/16/2005

Massachusetts General Hospital

Cancer and Leukemia Group B Summer Group Meeting 2010

Ser vice Recognition

5 years continued

19

Onsite Details

Hotel Information The Fairmont Chicago 200 North Columbus Drive, Chicago, Illinois 60601 800-441-1414 toll free 312-565-8000 local phone 312-856-1032 fax http://www.fairmont.com/chicago/ Location The hotel is about 18 miles from O’Hare International Airport and 13 miles from Midway International Airport; travel time is 30-60 minutes from either airport, depending on time of day, traffic and weather. Information on both airports is available on http://www.flychicago.com. Both airports are served by the Chicago Transit Authority, offering quick, easy public transportation from the airports to the downtown area. Local Temperature The normal high temperature for June in Chicago is 79 degrees; the normal low is 57 degrees. For a 10-day weather forecast, visit www.weather.com. Internet Access The hotel offers wireless Internet access throughout the Lobby Level and in the foyers of the 2nd, 3rd and B2 Levels. This service is available if guests have a laptop equipped with a wireless Network Interface card (N.I.C.) or built in wireless device to log directly into the Web portal. The cost of this service is $15.63 per use plus tax. Guests will be asked to input a credit card number at the appropriate field for automatic billing directly to the card. Ground Transportation Public Transportation - Chicago’s public transit system is an effective way to move around the city. A one-way ticket is $2.25 Daily and weekend passes are available. For more information, call CTA (Chicago Transit Authority) at 312-836-7000 or visit www.transitchicago.com Taxi - Available in front of the hotel. Parking - The hotel’s valet parking charges (including tax) are: Up to one hour: $20; one to two hours: $28 and two to 24 hours and overnight parking: $49.

future CALGB Meetings 2010 Fall Committee Meeting* September 23-25, 2010 Hilton Chicago O’Hare Airport Chicago, IL 2010 Fall Group Meeting November 11-13, 2010 The InterContinental Miami Miami, FL 2011 Spring Committee Meeting* March 2011 (date and hotel TBD) Chicago, IL 2011 Summer Group Meeting June 23-25, 2011 The Sheraton Boston Hotel Boston, MA 2011 Fall Committee Meeting* September 22-24, 2011 The InterContinental Chicago O’Hare Rosemont, IL *Closed meetings open to cadre members of committees or invited guests

20

Cancer and Leukemia Group B Summer Group Meeting 2010

The Fairmont Chicago / Hotel Floor Plans

Lobby Level

3rd Level

2nd Level

Lower Level

Acknowledgements The following have provided support to Cancer and Leukemia Group B research and educational programs in 2010. Abbott Laboratories Amgen, Inc. Breast Cancer Research Foundation Bristol-Myers Squibb Oncology Eisai, Inc. Genentech BioOncology Genomic Health Millennium Pharmaceuticals Network for Good Novartis Oncology OSI Pharmaceuticals Otsuka Pharmaceuticals Pfizer, Inc. Sanofi-Aventis Sigma-Tau Pharmaceuticals

The Cancer and Leukemia Group B is a national cooperative group of 25 of the most prestigious medical centers, and more than 200 affiliated institutions and 3,000 oncology specialists working together on large scale clinical trials.

Cancer and Leukemia Group B Central Office 230 West Monroe, Suite 2050 Chicago, IL 60606 www.calgb.org

Tomorrow’s Cancer Treatments Today